Browse/search for people

Publication - Professor Patrick Kehoe

    An investigation of antihypertensive class, dementia and cognitive decline. A meta-analysis.

    Citation

    Peters, R, Yasar, S, Anderson, C, Andrews, S, Antikainen, R, Beckett, N, Beer, JC, Bertens, AS, Booth, A, van Boxtel, M, Brayne, CEG, Brodaty, H, Carlson, MC, Chalmers, J, Corrada, M, DeKosky, S, Derby, C, Dixon, RA, Forette, F, Ganguli, M, van Gool, W, Guaita, A, Hever, A, Hogan, D, Jagger, C, Katz, M, Kawas, C, Kehoe, P, Keinanen-Kiukaanniemi, SM, Kenny, R, Köhler, S, Kunutsor, S, Laukkanen, J, Maxwell, C, McFall, GP, van Middelaar, T, van Charante, E, Tze-Pin, N, Peters, J, Rawtaer, I & others 2019, ‘An investigation of antihypertensive class, dementia and cognitive decline. A meta-analysis.’. Neurology.

    Abstract

    Objective
    High blood pressure is one of the main modifiable risk factors for dementia. However, there is conflicting evidence regarding the best antihypertensive class for optimising cognition. Our objective was to determine whether any particular class of antihypertensive was associated with a reduced risk of cognitive decline or
    dementia using comprehensive meta-analysis including reanalysis of original participant data.
    Methods
    To identify suitable studies MEDLINE, Embase and PsycINFO® and pre-existing study consortia were searched from inception to December 2017. Authors of prospective longitudinal human studies or trials of antihypertensives were contacted for data-sharing and collaboration. Outcome measures were incident
    dementia or incident cognitive decline (classified using the reliable change index method). Data were separated into mid and late-life (>65 years) and each antihypertensive class was compared to no treatment and to treatment with other antihypertensives. Meta-analysis was used to synthesize data.
    Results
    Over 50,000 participants from 27 studies were included. Among those aged >65 years, with the exception of diuretics, we found no relationship by class with incident cognitive decline or dementia. Diuretic use was suggestive of benefit in some analyses but results were not consistent across follow-up time, comparator
    group and outcome. Limited data precluded meaningful analyses in those ≤65 years.
    Conclusions
    Our findings, drawn from the current evidence base, support clinical freedom in the selection of antihypertensive regimens to achieve blood pressure goals.

    Full details in the University publications repository